AVAI
Avant Technologies Inc.0.3180
+0.0020+0.63%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
43.89MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
10-Q
Q3 FY2026 results
Avaí Bio posted no revenue for Q3 FY2026 ended December 31, 2025, with operating expenses up 19% y/y to $509.8k (derived), driven by $185k laboratory services and $55k marketing, yielding a net loss of $553.7k versus $452.3k last year; nine-month net loss narrowed 7% y/y to $1.5M (derived) as expenses fell 11%. Cash dwindled to $50k from $81k at FY start, with net operating cash use steady at ~$959k YTD and financing inflows funding $550k new loan payable alongside $698k related-party debt. Recent 50/50 JVs Klothonova (Sep 2025) and Insulinova (Nov 2025) with Austrianova tap cell encapsulation tech, AVAI funding up to $1.5M each. Cash burn persists.
10-Q
Q2 FY2026 results
Avant Technologies posted no revenue for Q2 FY2026 ended September 30, 2025, with operating loss shrinking 27% y/y to $394.7k from $623k, driven by slashed consulting and G&A costs while ramping R&D ($23.8k) and marketing ($80.6k). Six-month net loss narrowed 18% y/y to $940.6k, matching $0.01 diluted EPS across 137.5M shares. Cash edged up to $92k, but liabilities ballooned to $2.5M from related-party loans ($700k) and convertibles ($532k), funded by $623k financing inflows. Recent JVs with Ainnova (up to $20M commitment) and Austrianova (up to $1.5M) signal biotech pivot. Cash burn persists.
8-K
AVAI launches diabetes JV
Avant Technologies entered a joint venture agreement effective November 1, 2025, forming Insulinova, Inc. with Austrianova for diabetes treatments using encapsulated insulin cells. AVAI commits up to $1.5M funding for 18 months for 50% ownership, while Austrianova licenses its cell encapsulation IP. Deadlock risks board mediation. Funding caps exposure yet ties AVAI to biotech pivot.
8-K
AVAI-Austrianova biotech JV
Avant Technologies entered a joint venture with Austrianova on September 15, 2025, forming Klothonova Inc. to develop Klotho-overexpressing cell therapies for Alzheimer's, heart disease, cancer, kidney disease, and longevity. AVAI commits up to $1.5M equity for 18 months—50/50 split—while Austrianova licenses encapsulation tech; optional $8.5M loan follows. Deadlock risks linger. Board tied evenly.
IPO
Sector
Industry
ARAI
Arrive AI Inc.
3.29+0.05
AUR
Aurora Innovation, Inc.
4.12-0.06
DVLT
Datavault AI Inc.
1.39+0.11
FYNN
Fyntechnical Innovations, Inc.
0.00+0.00
GTCH
GBT Technologies Inc.
0.00-0.00
JTAI
Jet.AI Inc.
1.17-0.07
NXTT
Next Technology Holding Inc.
6.73-0.17
SNOW
Snowflake Inc.
220.60+5.32
TSPH
CreateAI Holdings Inc.
0.14-0.02
VRSSF
VERSES AI INC.
2.20+0.02